Immunoclin (Immunoclin) Change In Receivables : $-0.06 Mil (TTM As of Oct. 2014)

View and export this data going back to 2012. Start your Free Trial

What is Immunoclin Change In Receivables?

Immunoclin's change in receivables for the quarter that ended in Oct. 2014 was $-0.06 Mil. It means Immunoclin's Accounts Receivable increased by $0.06 Mil from Jul. 2014 to Oct. 2014 .

Immunoclin's change in receivables for the fiscal year that ended in Jan. 2014 was $0.01 Mil. It means Immunoclin's Accounts Receivable declined by $0.01 Mil from Jan. 2013 to Jan. 2014 .

Immunoclin's Accounts Receivable for the quarter that ended in Oct. 2014 was $0.07 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Immunoclin's Days Sales Outstanding for the three months ended in Oct. 2014 was 1,222.75.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Immunoclin's liquidation value for the three months ended in Oct. 2014 was $-2.64 Mil.

Immunoclin Change In Receivables Historical Data

The historical data trend for Immunoclin's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunoclin Change In Receivables Chart

Immunoclin Annual Data

Trend

Feb12

Jan13

Jan14

Change In Receivables

0.12

0.01

Immunoclin Quarterly Data
	May11	Aug11	Nov11	Feb12	May12	Aug12	Nov12	Feb13	May13	Aug13	Nov13	Apr14	Jul14	Oct14
Change In Receivables	Get a 7-Day Free Trial									-	-	-0.01	0.01	-0.06

Immunoclin Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Oct. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06 Mil.

Immunoclin (GREY:IMCL) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Immunoclin's Days Sales Outstanding for the quarter that ended in Oct. 2014 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.067	/	0.005	*	91
=	1,222.75

2. In Ben Graham's calculation of liquidation value, Immunoclin's accounts receivable are only considered to be worth 75% of book value:

Immunoclin's liquidation value for the quarter that ended in Oct. 2014 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.146	-	2.84	+	0.75 * 0.067	+	0.5 * 0
=	-2.64

Immunoclin Change In Receivables Related Terms

Thank you for viewing the detailed overview of Immunoclin's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunoclin (Immunoclin) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunoclin Corp (GREY:IMCL) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

9107 Wilshire Boulevard, Suite 450, Beverly Hills, CA, USA, 90210

Website

http://www.immunoclin.com

Immunoclin Corp is engaged in immunology research and development skill to serve the pharmaceutical, biotechnology and food industries, providing comprehensive, clinical and basic science research expertise at a commercial scale and quality.

Immunoclin (Immunoclin) Headlines

No Headlines